We show that fadraciclib demonstrates improved kinase inhibitory potency in vitro against its primary CDK targets–CDK2 and CDK9 (Fig 1B)–as well as anti-cancer activity in in vitro and in vivo models (Fig 7). The gene discussed is CDK2; the disease is cancer.